ANDREA PFEIFER,CLAUDE NICOLAU,RUTH GREFERATH,DAVID HICKMAN,ANDREAS MUHS
申请号：
MX2012002392
公开号：
MX358175B
申请日:
2006.12.08
申请国别(地区):
MX
年份:
2018
代理人:
摘要：
The present invention is related to methods and compositions for the therapeutic and diagnostic use in the treatment of diseases and disorders which are caused by or associated with amyloid or amyloid-like proteins including amyloidosis, a group of disorders and abnormalities associated with amyloid protein such as Alzheimer's disease. The present invention provides novel methods and compositions comprising highly specific and highly effective antibodies having the ability to specifically recognize and bind to specific epitopes from a range of ß-amyloid proteins. The antibodies enabled by the teaching of the present invention are particularly useful for the treatment of diseases and disorders which are caused by or associated with amyloid or amyloid-like proteins including amyloidosis, a group of diseases and disorders associated with amyloid plaque formation including secondary amyloidosis and age-related amyloidosis including, but not limited to, neurological disorders such as Alzheimer's Disease (AD).La presente invención se refiere a una formula humanizada de un anticuerpo obtenible del hibridoma depositado el 1° de diciembre de 2005 bajo el número de acceso DSMA CC2751, o un fragmento del mismo, en donde el anticuerpo es humanizado al insertar regiones determinantes de complementariedad (CDR) del anticuerpo en una estructura humana, en donde la forma humanizada del anticuerpo o el fragmento del mismo se une a ß-amiloide.
